-
1
-
-
23444432920
-
The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications
-
LAMBERT DM, FOWLER CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med Chem. (2005) 48:5059-5087.
-
(2005)
J. Med Chem.
, vol.48
, pp. 5059-5087
-
-
Lambert, D.M.1
Fowler, C.J.2
-
2
-
-
18444376760
-
International union of pharmacology. XXVII. Classification of cannabinoid receptors
-
HOWLETT AC, BARTH F, BONNER TI et al.: International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
-
(2002)
Pharmacol. Rev.
, vol.54
, pp. 161-202
-
-
Howlett, A.C.1
Barth, F.2
Bonner, T.I.3
-
3
-
-
0037177601
-
Endocannabinoid signaling in the brain
-
WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
-
(2002)
Science
, vol.29
, pp. 678-682
-
-
Wilson, R.I.1
Nicoll, R.A.2
-
4
-
-
33144480327
-
Cannabinoid receptors as therapeutic targets
-
MACKIE K: Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. (2006) 46:101-122.
-
(2006)
Annu. Rev. Pharmacol. Toxicol.
, vol.46
, pp. 101-122
-
-
Mackie, K.1
-
5
-
-
27844463517
-
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
-
DESPRES JP, GOLAY A, SJOESTROEM L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl. J. Med. (2005) 353:2121-2134.
-
(2005)
New Engl. J. Med.
, vol.353
, pp. 2121-2134
-
-
Despres, J.P.1
Golay, A.2
Sjoestroem, L.3
-
6
-
-
17144382751
-
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
-
VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
-
(2005)
Lancet
, vol.1365
, pp. 1389-1397
-
-
Van Gaal, L.F.1
Rissanen, A.M.2
Scheen, A.J.3
Ziegler, O.4
Rossner, S.5
-
7
-
-
32644441249
-
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-north america: A randomized controlled trial
-
RIO-NORTH AMERICAN STUDY GROUP:
-
PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J; RIO-NORTH AMERICAN STUDY GROUP: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-north america: a randomized controlled trial. J. Am. Med. Assoc. (2006) 295:761-775.
-
(2006)
J. Am. Med. Assoc.
, vol.295
, pp. 761-775
-
-
Pi-sunyer, F.X.1
Aronne, L.J.2
Heshmati, H.M.3
Devin, J.4
Rosenstock, J.5
-
8
-
-
33646481040
-
Rimonabant: A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors
-
GELFAND EV, CANNON CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. (2006) 47:1919-1926.
-
(2006)
J. Am. Coll. Cardiol.
, vol.47
, pp. 1919-1926
-
-
Gelfand, E.V.1
Cannon, C.P.2
-
9
-
-
2942556913
-
Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure
-
CLELAND JG, GHOSH J, FREEMANTLE N et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Failure (2004) 6:501-508.
-
(2004)
Eur. J. Heart Failure
, vol.6
, pp. 501-508
-
-
Cleland, J.G.1
Ghosh, J.2
Freemantle, N.3
-
10
-
-
33745003240
-
1 cannabinoid receptor antagonism: A new strategy for the treatment of 1iver fibrosis
-
1 cannabinoid receptor antagonism: a new strategy for the treatment of 1iver fibrosis. Nat. Med. (2006) 12:671-676.
-
(2006)
Nat. Med.
, vol.12
, pp. 671-676
-
-
Teixeira-clerc, F.1
Julien, B.2
Grenard, P.3
-
11
-
-
0029034879
-
Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist
-
RINALDI-CARMONA M, BARTH F, HEAULME M et al.: Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. (1995) 56:1941-1947.
-
(1995)
Life Sci.
, vol.56
, pp. 1941-1947
-
-
Rinaldi-carmona, M.1
Barth, F.2
Heaulme, M.3
-
12
-
-
19444368081
-
1 cannabinoid receptor antagonists. Drug Discov
-
1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
-
(2005)
Today
, vol.10
, pp. 693-702
-
-
Lange, J.H.1
Kruse, C.G.2
-
13
-
-
0032787760
-
The development of cannabinoid antagonists
-
BARTH F, RINALDI-CARMONA M: The development of cannabinoid antagonists. Cur. Med. Chem. (1999) 6:745-755.
-
(1999)
Cur. Med. Chem.
, vol.6
, pp. 745-755
-
-
Barth, F.1
Rinaldi-Carmona, M.2
-
14
-
-
0033815067
-
Recent advances in cannabinoid receptor agonists and antagonists
-
GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 10:1529-1538.
-
(2000)
Expert Opin. Ther. Patents
, vol.10
, pp. 1529-1538
-
-
Goya, P.1
Jagerovic, N.2
-
15
-
-
0036799598
-
Recent advances in the cannabinoids
-
ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2002) 12:1475-1489.
-
(2002)
Expert Opin. Ther. Patents
, vol.12
, pp. 1475-1489
-
-
Adam, J.1
Cowley, P.2
-
17
-
-
5744223570
-
Recent advances in the cannabinoids
-
HERTZOG DL: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2004) 14:1435-1452.
-
(2004)
Expert Opin. Ther. Patents
, vol.14
, pp. 1435-1452
-
-
Hertzog, D.L.1
-
18
-
-
21044458324
-
Current knowledge on the antagonists and inverse agonists of cannabinoid receptors
-
MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Cur. Med. Chem. (2005) 12:1361-1394.
-
(2005)
Cur. Med. Chem.
, vol.12
, pp. 1361-1394
-
-
Muccioli, G.G.1
Lambert, D.M.2
-
24
-
-
33244484802
-
1 antagonist SR141716: Synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides
-
1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur. J. Med. Chem. (2006) 41:114-120.
-
(2006)
Eur. J. Med. Chem.
, vol.41
, pp. 114-120
-
-
Jagerovic, N.1
Hernandez-folgado, L.2
Alkorta, I.3
-
27
-
-
16244420759
-
Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo(g]-indazole-based ligands for cannabinoid receptors
-
MURINEDDU G, RUIU S, MUSSINU JM et al.: Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo(g]-indazole-based ligands for cannabinoid receptors. Bioorg. Med. Chem. (2005) 13:3309-3320.
-
(2005)
Bioorg. Med. Chem.
, vol.13
, pp. 3309-3320
-
-
Murineddu, G.1
Ruiu, S.2
Mussinu, J.M.3
-
28
-
-
28544446066
-
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichloro phenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydr obenzo[6,7]cyclohepta[1,2-c]pyrazole-3-car boxamide
-
MURINEDDU G, RUIU S, LORIGA G et al.: Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichloro phenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydr obenzo[6,7]cyclohepta[1,2-c]pyrazole-3-car boxamide. J. Med. Chem. (2005) 48:7351-7362.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 7351-7362
-
-
Murineddu, G.1
Ruiu, S.2
Loriga, G.3
-
30
-
-
0041321275
-
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
-
FU J, GAETANI S, OVEISI F et al.: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature (2003) 425:90-93.
-
(2003)
Nature
, vol.425
, pp. 90-93
-
-
Fu, J.1
Gaetani, S.2
Oveisi, F.3
-
31
-
-
3142583174
-
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α)
-
GUZMAN M, LO VERME J, FU F, OVEISI F, BLAZQUEZ C, PIOMELLI D: Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α). J. Biol. Chem. (2004) 279:27849-27854.
-
(2004)
J. Biol. Chem.
, vol.279
, pp. 27849-27854
-
-
Guzman, M.1
Lo Verme, J.2
Fu, F.3
Oveisi, F.4
Blazquez, C.5
Piomelli, D.6
-
32
-
-
0042190566
-
Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype
-
SEGAL-LIEBERMAN G, BRADLEY RL, KOKKOTOU E et al.: Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. USA (2003) 100:10085-10090.
-
(2003)
Proc Natl. Acad. Sci. USA
, vol.100
, pp. 10085-10090
-
-
Segal-lieberman, G.1
Bradley, R.L.2
Kokkotou, E.3
-
33
-
-
0035142565
-
Synergistic effects of opioid and cannabinoid antagonists on food intake
-
(Berlin, Germany)
-
KIRKHAM TC, WILLIAMS CM: Synergistic effects of opioid and cannabinoid antagonists on food intake. (Berlin, Germany) Psychopharmacology (2001) 153:267-270.
-
(2001)
Psychopharmacology
, vol.153
, pp. 267-270
-
-
Kirkham, T.C.1
Williams, C.M.2
-
35
-
-
22544439953
-
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
-
IDRIS AI, VAN'T HOF RJ, GREIG IR et al.: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. (2005) 11:774-779
-
(2005)
Nat. Med.
, vol.11
, pp. 774-779
-
-
Idris, A.I.1
Van't Hof, R.J.2
Greig, I.R.3
-
38
-
-
25444464434
-
2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice
-
2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur. J. Pharmacol. (2005) 520:164-171.
-
(2005)
Eur. J. Pharmacol.
, vol.520
, pp. 164-171
-
-
Ueda, Y.1
Miyagawa, N.2
Matsui, T.3
Kaya, T.4
Iwamura, H.5
-
41
-
-
24344509882
-
Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies
-
SHANKAR BB, LAVEY BJ, ZHOU G et al.: Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Letters (2005) 15:4417-4420.
-
(2005)
Bioorg. Med. Chem. Letters
, vol.15
, pp. 4417-4420
-
-
Shankar, B.B.1
Lavey, B.J.2
Zhou, G.3
-
42
-
-
33748780355
-
2) expression and pharmacology using a novel radioligand
-
35S]SCH225336 ahead of print June 206 DOI 10.1074 /jbc.M602364200
-
35S]SCH225336. J. Biol. Chem. (2006) ahead of print June 206 DOI 10.1074/jbc.M602364200.
-
(2006)
J. Biol. Chem.
-
-
Gonsiorek, W.1
Hesk, D.2
Kinsley, D.3
-
43
-
-
31144468211
-
A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo
-
LUNN CA, FINE JS, ROJAS-TRIANA A et al.: A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. (2006) 316:780-788.
-
(2006)
J. Pharmacol. Exp. Ther.
, vol.316
, pp. 780-788
-
-
Lunn, C.A.1
Fine, J.S.2
Rojas-Triana, A.3
-
45
-
-
0028129936
-
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
-
RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
-
(1994)
FEBS Lett.
, vol.350
, pp. 240-244
-
-
Rinaldi-carmona, M.1
Barth, F.2
Heaulme, M.3
-
46
-
-
85047690626
-
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
-
COTA D, MARSICANO G, TSCHOP M et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. (2003) 112:423-431.
-
(2003)
J. Clin. Invest.
, vol.112
, pp. 423-431
-
-
Cota, D.1
Marsicano, G.2
Tschop, M.3
-
47
-
-
1842866963
-
1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
-
1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. (2004) 28:640-648.
-
(2004)
Int. J. Obes.
, vol.28
, pp. 640-648
-
-
Ravinet Trillou, C.1
Delgorge, C.2
Menet, C.3
Arnone, M.4
Soubrie, P.5
-
48
-
-
33645519808
-
How many sites of action for endocannabinoids to control energy metabolism?
-
PAGOTTO U, CERVINO C, VICENNATI V, MARSICANO G, LUTZ B, PASQUALI R: How many sites of action for endocannabinoids to control energy metabolism? Int. J. Obes. (2006) 30:S39-S43.
-
(2006)
Int. J. Obes.
, vol.30
-
-
Pagotto, U.1
Cervino, C.2
Vicennati, V.3
Marsicano, G.4
Lutz, B.5
Pasquali, R.6
-
49
-
-
0037374766
-
1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
-
1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. (2003) 63:908-914.
-
(2003)
Mol. Pharmacol.
, vol.63
, pp. 908-914
-
-
Bensaid, M.1
Gary-bobo, M.2
Esclangon, A.3
-
50
-
-
12744260206
-
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile
-
POIRIER B, BIDOUARD JP, CADROUVELE C et al.: The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. (2005) 7:65-72.
-
(2005)
Diabetes Obes. Metab.
, vol.7
, pp. 65-72
-
-
Poirier, B.1
Bidouard, J.P.2
Cadrouvele, C.3
-
51
-
-
12744258029
-
1 receptors
-
1 receptors. Life Sci. (2005) 76:1307-1324.
-
(2005)
Life Sci.
, vol.76
, pp. 1307-1324
-
-
Pertwee, R.G.1
-
52
-
-
29844447996
-
Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'
-
GARDNER A, MALLET PE: Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur. J. Pharmacol. (2006) 530:103-106.
-
(2006)
Eur. J. Pharmacol.
, vol.530
, pp. 103-106
-
-
Gardner, A.1
Mallet, P.E.2
|